Generate Biomedicines (GENB)
Market Price (7/10/2026): $15.64 | Market Cap: $1.0 BilSector: Health Care | Industry: Biotechnology
Generate Biomedicines (GENB)
Market Price (7/10/2026): $15.64Market Cap: $1.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -12%, 3Y Excs Rtn is -45% | Key risksGENB key risks include [1] a precarious financial position due to its high valuation and limited cash runway, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -44% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -12%, 3Y Excs Rtn is -45% |
| Key risksGENB key risks include [1] a precarious financial position due to its high valuation and limited cash runway, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/7/2026
Generate Biomedicines (GENB) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Advancement of a broad clinical pipeline and key program designations. Generate Biomedicines announced significant progress in its clinical portfolio during its fiscal Q1 2026, which ended March 31, 2026. Its lead candidate, GB-0895 (an anti-TSLP antibody), continues to advance in global Phase 3 clinical trials for severe asthma (SOLAIRIA-1 and SOLAIRIA-2) and a Phase 1b trial for COPD. The company also activated clinical trial sites for GB-4362 (MMAE neutralizer), which received FDA Fast Track designation, with the first patient expected to be dosed in mid-2026. Additionally, the first patient dosing for GB-5267 (MUC16 armored CAR T) in a Phase 1 trial for solid tumors is anticipated in the second half of 2026. These milestones signal strong execution on its development programs and potential future value.
2. Robust cash position following its Initial Public Offering (IPO). Generate Biomedicines' financial stability was significantly bolstered by its IPO, completed on March 2, 2026, which generated $369.3 million in net proceeds. This contributed to a strong cash, cash equivalents, and marketable securities balance of approximately $516.6 million as of March 31, 2026, providing a projected funding runway into the first half of 2028. This substantial capital infusion helps de-risk the company's extensive clinical development programs.
Show more
Generate Biomedicines (GENB) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Advancement of a broad clinical pipeline and key program designations. Generate Biomedicines announced significant progress in its clinical portfolio during its fiscal Q1 2026, which ended March 31, 2026. Its lead candidate, GB-0895 (an anti-TSLP antibody), continues to advance in global Phase 3 clinical trials for severe asthma (SOLAIRIA-1 and SOLAIRIA-2) and a Phase 1b trial for COPD. The company also activated clinical trial sites for GB-4362 (MMAE neutralizer), which received FDA Fast Track designation, with the first patient expected to be dosed in mid-2026. Additionally, the first patient dosing for GB-5267 (MUC16 armored CAR T) in a Phase 1 trial for solid tumors is anticipated in the second half of 2026. These milestones signal strong execution on its development programs and potential future value.
2. Robust cash position following its Initial Public Offering (IPO). Generate Biomedicines' financial stability was significantly bolstered by its IPO, completed on March 2, 2026, which generated $369.3 million in net proceeds. This contributed to a strong cash, cash equivalents, and marketable securities balance of approximately $516.6 million as of March 31, 2026, providing a projected funding runway into the first half of 2028. This substantial capital infusion helps de-risk the company's extensive clinical development programs.
Show more
Updated on 7/7/2026
Generate Biomedicines (GENB) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Advancement of a broad clinical pipeline and key program designations. Generate Biomedicines announced significant progress in its clinical portfolio during its fiscal Q1 2026, which ended March 31, 2026. Its lead candidate, GB-0895 (an anti-TSLP antibody), continues to advance in global Phase 3 clinical trials for severe asthma (SOLAIRIA-1 and SOLAIRIA-2) and a Phase 1b trial for COPD. The company also activated clinical trial sites for GB-4362 (MMAE neutralizer), which received FDA Fast Track designation, with the first patient expected to be dosed in mid-2026. Additionally, the first patient dosing for GB-5267 (MUC16 armored CAR T) in a Phase 1 trial for solid tumors is anticipated in the second half of 2026. These milestones signal strong execution on its development programs and potential future value.
2. Robust cash position following its Initial Public Offering (IPO). Generate Biomedicines' financial stability was significantly bolstered by its IPO, completed on March 2, 2026, which generated $369.3 million in net proceeds. This contributed to a strong cash, cash equivalents, and marketable securities balance of approximately $516.6 million as of March 31, 2026, providing a projected funding runway into the first half of 2028. This substantial capital infusion helps de-risk the company's extensive clinical development programs.
3. Positive analyst sentiment and increased price targets. The company received favorable attention from Wall Street analysts, with several firms maintaining or upgrading their ratings and price targets for GENB shares. For instance, HC Wainwright & Co. raised its price target from $16.00 to $25.00 on May 8, 2026, while Morgan Stanley increased its target from $20.00 to $22.00 on May 14, 2026. The consensus average 12-month price target across analysts reached $25.40, indicating a potential upside of approximately 47.50% to 56.6% from the stock's recent trading levels.
4. Significant institutional investment reflecting confidence. Investor confidence in Generate Biomedicines was further evidenced by a substantial institutional investment. HarbourVest Partners disclosed a new position in Generate Biomedicines during fiscal Q1 2026, acquiring 1,722,210 shares with an estimated transaction value of $21.03 million. This new, sizable stake by a prominent investment firm highlights a strong belief in the company's long-term prospects.
5. Favorable macroeconomic environment for the biotech sector. The broader biotech market experienced a rebound in fiscal Q2 2026, with a significant easing of layoffs and improving financing conditions, including a more open IPO window. Venture capital returned to emerging biotechs, particularly favoring later-stage, clinically validated assets. Clinical-stage funding increased by 55% in 2025, creating a supportive backdrop for companies like Generate Biomedicines with advanced pipelines.
Show less
Generate Biomedicines (GENB) stock has gained about 25% since 3/31/2026 because of the following key factors:
1. Advancement of a broad clinical pipeline and key program designations. Generate Biomedicines announced significant progress in its clinical portfolio during its fiscal Q1 2026, which ended March 31, 2026. Its lead candidate, GB-0895 (an anti-TSLP antibody), continues to advance in global Phase 3 clinical trials for severe asthma (SOLAIRIA-1 and SOLAIRIA-2) and a Phase 1b trial for COPD. The company also activated clinical trial sites for GB-4362 (MMAE neutralizer), which received FDA Fast Track designation, with the first patient expected to be dosed in mid-2026. Additionally, the first patient dosing for GB-5267 (MUC16 armored CAR T) in a Phase 1 trial for solid tumors is anticipated in the second half of 2026. These milestones signal strong execution on its development programs and potential future value.
2. Robust cash position following its Initial Public Offering (IPO). Generate Biomedicines' financial stability was significantly bolstered by its IPO, completed on March 2, 2026, which generated $369.3 million in net proceeds. This contributed to a strong cash, cash equivalents, and marketable securities balance of approximately $516.6 million as of March 31, 2026, providing a projected funding runway into the first half of 2028. This substantial capital infusion helps de-risk the company's extensive clinical development programs.
3. Positive analyst sentiment and increased price targets. The company received favorable attention from Wall Street analysts, with several firms maintaining or upgrading their ratings and price targets for GENB shares. For instance, HC Wainwright & Co. raised its price target from $16.00 to $25.00 on May 8, 2026, while Morgan Stanley increased its target from $20.00 to $22.00 on May 14, 2026. The consensus average 12-month price target across analysts reached $25.40, indicating a potential upside of approximately 47.50% to 56.6% from the stock's recent trading levels.
4. Significant institutional investment reflecting confidence. Investor confidence in Generate Biomedicines was further evidenced by a substantial institutional investment. HarbourVest Partners disclosed a new position in Generate Biomedicines during fiscal Q1 2026, acquiring 1,722,210 shares with an estimated transaction value of $21.03 million. This new, sizable stake by a prominent investment firm highlights a strong belief in the company's long-term prospects.
5. Favorable macroeconomic environment for the biotech sector. The broader biotech market experienced a rebound in fiscal Q2 2026, with a significant easing of layoffs and improving financing conditions, including a more open IPO window. Venture capital returned to emerging biotechs, particularly favoring later-stage, clinically validated assets. Clinical-stage funding increased by 55% in 2025, creating a supportive backdrop for companies like Generate Biomedicines with advanced pipelines.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
3/31/2026 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GENB | 25.8% | |
| Market (SPY) | 15.6% | 17.4% |
| Sector (XLV) | 10.6% | 22.4% |
Fundamental Drivers
nullnull
Market Drivers
12/31/2025 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GENB | ||
| Market (SPY) | 10.5% | 20.4% |
| Sector (XLV) | 5.2% | 22.3% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2025 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GENB | ||
| Market (SPY) | 22.7% | 20.4% |
| Sector (XLV) | 21.9% | 22.3% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GENB | ||
| Market (SPY) | 75.6% | 20.4% |
| Sector (XLV) | 27.9% | 22.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GENB Return | - | - | - | - | - | 25% | 25% |
| Peers Return | -42% | -52% | 10% | -55% | 12% | 46% | -78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| GENB Win Rate | - | - | - | - | - | 50% | |
| Peers Win Rate | 36% | 37% | 48% | 35% | 55% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| GENB Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -68% | -66% | -64% | -67% | -55% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SDGR, RXRX, ABCL, RLAY, DNA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/9/2026 (YTD)
How Low Can It Go
GENB has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
GENB has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Generate Biomedicines (GENB)
Generate Biomedicines (GENB) is a clinical-stage generative biology company that leverages artificial intelligence to transform drug design and development. The company's core asset is its proprietary "Generate Platform," an AI-driven system that integrates advanced computational models with scalable biohardware. This platform operates through a continuous design-build-test-learn loop, enabling the creation of novel therapeutics, including the de novo design of proteins, by generating and rapidly verifying biological hypotheses at scale.
The company's pipeline includes several computationally engineered drug candidates. Its most advanced product, GB-0895, is a long-acting anti-TSLP monoclonal antibody currently enrolling patients in pivotal Phase 3 clinical trials for severe asthma, with a targeted Q26W (every six months) dosing regimen to improve patient adherence. GB-0895 is also undergoing evaluation in a Phase 1b clinical trial for moderate-to-severe chronic obstructive pulmonary disease (COPD). Additionally, Generate Biomedicines expects to advance two oncology candidates, GB-4362 (an antibody designed to neutralize free MMAE as an adjunctive therapy for ADCs) and GB-5267 (an armored, MUC16-directed CAR-T cell therapy for solid tumors), into Phase 1 trials in 2026.
Generate Biomedicines aims to address substantial unmet medical needs across a range of therapeutic areas, serving patients with conditions like severe asthma, COPD, and various solid tumors. Beyond its internal pipeline, the Generate Platform is also the foundation for confidential drug development programs in collaboration with major pharmaceutical partners such as Amgen and Novartis, demonstrating the platform's broad applicability and potential for generating innovative medicines across diverse disease indications.
AI Analysis | Feedback
Generate Biomedicines is like **Moderna, but for AI-designed proteins and drugs instead of mRNA.**
Generate Biomedicines is like An OpenAI for drug discovery, leveraging generative AI to design novel medicines.
AI Analysis | Feedback
Generate Biomedicines (GENB) offers the following major products:
- Generate Platform: A proprietary AI-driven generative biology platform designed to program biology and generate optimal therapeutics across various modalities.
- GB-0895: An investigational long-acting anti-TSLP monoclonal antibody currently in pivotal Phase 3 clinical trials for severe asthma and Phase 1b for COPD.
- GB-4362: A monoclonal antibody developed as an adjunctive therapy to neutralize free MMAE, used with antibody-drug conjugate molecules.
- GB-5267: An armored, MUC16-directed CAR-T cell therapy candidate being developed for solid tumors, specifically targeting platinum-resistant ovarian cancer.
AI Analysis | Feedback
```html
Generate Biomedicines (GENB) primarily sells to other companies through collaborations. The major customer companies mentioned in the provided description are:
- Amgen Inc. (AMGN)
- Novartis Pharma AG (NVS)
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Generate Biomedicines (GENB) faces several key risks inherent to its business model as a clinical-stage generative biology company:
- Clinical Trial Failure and Regulatory Approval Challenges: The company's success heavily relies on the successful outcome of its ongoing and planned clinical trials for product candidates such as GB-0895 (in pivotal Phase 3 trials for severe asthma and Phase 1b for COPD) and other oncology candidates (expected to advance into Phase 1 in 2026). Failure of these trials to demonstrate safety and efficacy, or an inability to obtain necessary regulatory approvals from agencies like the FDA, would significantly impede the company's ability to commercialize its products and generate revenue.
- Dependence on the Efficacy of its Proprietary Generate Platform: Generate Biomedicines' core strategy is built around its proprietary "Generate Platform," an AI-driven system for drug design and development. The platform's ability to consistently generate optimal therapeutics, learn generalizable design principles, and integrate with advanced experimental biohardware is fundamental to the company's pipeline. Any limitations, inefficiencies, or failures in the platform's ability to produce viable and differentiated molecular solutions could undermine the company's long-term success and ability to develop new product candidates.
- Intense Competition in the Biotechnology and Pharmaceutical Industry: The fields of severe asthma, COPD, and oncology are highly competitive, with established pharmaceutical companies and other biotechnology firms developing and marketing treatments. Even if Generate Biomedicines' product candidates receive regulatory approval, they will face significant competition from existing therapies, including biologics, and new entrants. This competition could impact market adoption, pricing, and overall commercial success of the company's therapeutic offerings.
AI Analysis | Feedback
null
AI Analysis | Feedback
Generate Biomedicines (symbol: GENB) has the following addressable market sizes for its main products:
-
GB-0895 for severe asthma:
- The global severe asthma treatment market is valued at approximately USD 24.30 billion in 2025 and is projected to reach USD 39.96 billion by 2035.
- The U.S. severe asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033.
-
GB-0895 for moderate-to-severe COPD:
- The global chronic obstructive pulmonary disease (COPD) treatment market size is expected to be valued at USD 21.04 billion in 2025 and is anticipated to reach around USD 34.59 billion by 2035.
- North America generated more than 42% of the revenue share in 2025 for the COPD treatment market.
- GB-4362 (adjunctive therapy to ADC molecules with an MMAE payload): null
- GB-5267 (armored, MUC16-directed CAR-T cell therapy for solid tumors, initially targeting platinum-resistant ovarian cancer): null
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Generate Biomedicines (GENB)
- Advancement and Potential Approval of GB-0895 for Severe Asthma: Generate Biomedicines' lead product candidate, GB-0895, an investigational long-acting anti-TSLP monoclonal antibody, is currently enrolling patients in two pivotal global Phase 3 clinical trials (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with the first patient dosed in January 2026. Successful progression through these trials and eventual market approval within the next 2-3 years would be a significant driver of revenue growth, especially given its potential for a Q26W dosing regimen and ultra-high binding affinity, which could address adherence challenges with existing therapies.
- Expansion of GB-0895 into Chronic Obstructive Pulmonary Disease (COPD): In parallel with its severe asthma program, Generate Biomedicines is conducting a Phase 1b clinical trial for GB-0895 in moderate-to-severe COPD, with data expected in 2026. Positive results from this trial and subsequent advancement into later-stage development would open up a new and substantial market for GB-0895, significantly broadening its revenue potential beyond severe asthma.
- Progression of Oncology Product Candidates into Clinical Trials: The company expects to advance two additional computationally generated oncology product candidates, GB-4362 and GB-5267, into Phase 1 clinical trials in 2026, following the clearance of their Investigational New Drug (IND) applications in December 2025. While direct product revenue from these programs is further out, their successful initiation and early clinical data will validate the Generate Platform and could trigger milestone payments from potential future partnerships or collaborations, contributing to revenue growth.
- Milestone Payments from Strategic Collaborations: Generate Biomedicines has established confidential programs with Amgen Inc. and Novartis Pharma AG, which leverage its Generate Platform. As these collaborative programs advance through preclinical and clinical development stages, they are expected to trigger milestone payments, providing a source of non-product revenue growth over the next 2-3 years.
AI Analysis | Feedback
Inbound Investments
- Generate Biomedicines has confidential programs under development in collaboration with Amgen Inc. and Novartis Pharma AG.
Capital Expenditures
- Generate Biomedicines has invested in scalable biohardware systems, encompassing DNA assembly, rapid protein production, and high-throughput, multiplexed assay miniaturization.
- The company has established a cryogenic electron microscopy ("Cryo-EM") core, which generated over 500 high-resolution maps in 2025.
- These capital investments are focused on reducing the cost and time per assay data point, thereby strengthening the link between generative models and real-world biological verification.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.73 |
| Mkt Cap | 1.6 |
| Rev LTM | 79 |
| Op Inc LTM | -292 |
| FCF LTM | -189 |
| FCF 3Y Avg | -258 |
| CFO LTM | -166 |
| CFO 3Y Avg | -247 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.6% |
| Rev Chg 3Y Avg | 13.1% |
| Rev Chg Q | -49.1% |
| QoQ Delta Rev Chg LTM | -11.5% |
| Op Inc Chg LTM | 21.6% |
| Op Inc Chg 3Y Avg | -6.5% |
| Op Mgn LTM | -249.8% |
| Op Mgn 3Y Avg | -726.0% |
| QoQ Delta Op Mgn LTM | -17.5% |
| CFO/Rev LTM | -193.5% |
| CFO/Rev 3Y Avg | -216.2% |
| FCF/Rev LTM | -238.9% |
| FCF/Rev 3Y Avg | -405.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 |
|---|---|---|
| Field of generative biology by using machine learning for drug discovery and development through the | 32 | 20 |
| Total | 32 | 20 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Field of generative biology by using machine learning for drug discovery and development through the | -203 | -174 |
| Total | -203 | -174 |
Price Behavior
null
GENB Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.93 | 1.52 | 1.44 | -0.15 | 0.64 | 0.03 |
| Up Beta | 2.69 | 0.82 | 1.80 | 1.35 | -0.05 | -0.68 |
| Down Beta | 6.67 | 2.65 | 2.05 | -1.16 | -0.92 | 0.37 |
| Up Capture | 176% | 252% | 167% | 92% | 40% | 4% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 24 | 35 | 45 | 45 | 45 |
| Down Capture | -126% | 65% | 65% | 43% | 28% | 15% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 17 | 28 | 39 | 39 | 39 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GENB | |
|---|---|---|---|---|
| GENB | 24.4% | 90.9% | 1.08 | - |
| Sector ETF (XLV) | 21.8% | 15.7% | 1.06 | 22.3% |
| Equity (SPY) | 22.3% | 12.5% | 1.33 | 20.4% |
| Gold (GLD) | 24.4% | 27.8% | 0.77 | -4.7% |
| Commodities (DBC) | 23.6% | 18.7% | 1.00 | -7.8% |
| Real Estate (VNQ) | 13.2% | 13.9% | 0.65 | 2.5% |
| Bitcoin (BTCUSD) | -42.8% | 42.8% | -1.18 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GENB | |
|---|---|---|---|---|
| GENB | 4.4% | 90.9% | 1.08 | - |
| Sector ETF (XLV) | 6.8% | 14.9% | 0.27 | 22.3% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 20.4% |
| Gold (GLD) | 18.0% | 18.3% | 0.80 | -4.7% |
| Commodities (DBC) | 7.5% | 19.5% | 0.28 | -7.8% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.06 | 2.5% |
| Bitcoin (BTCUSD) | 12.3% | 53.5% | 0.42 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GENB | |
|---|---|---|---|---|
| GENB | 2.2% | 90.9% | 1.08 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.52 | 22.3% |
| Equity (SPY) | 15.8% | 17.9% | 0.75 | 20.4% |
| Gold (GLD) | 11.7% | 16.1% | 0.59 | -4.7% |
| Commodities (DBC) | 6.1% | 18.0% | 0.27 | -7.8% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.22 | 2.5% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -11.2% | 6.0% | -15.9% |
| SUMMARY STATS | |||
| # Positive | 0 | 1 | 0 |
| # Negative | 1 | 0 | 1 |
| Median Positive | 6.0% | ||
| Median Negative | -11.2% | -15.9% | |
| Max Positive | 6.0% | ||
| Max Negative | -11.2% | -15.9% | |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -11.2% | 6.0% | -15.9% |
| SUMMARY STATS | |||
| # Positive | 0 | 1 | 0 |
| # Negative | 1 | 0 | 1 |
| Median Positive | 6.0% | ||
| Median Negative | -11.2% | -15.9% | |
| Max Positive | 6.0% | ||
| Max Negative | -11.2% | -15.9% | |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nally, Michael | Chief Executive Officer | Direct | Buy | 3062026 | 12.00 | 20,000 | 240,000 | 6,872,484 | Form |
| 2 | Grous, Beth | Chief People Officer | Spouse | Buy | 3022026 | 16.00 | 300 | 4,800 | 4,800 | Form |
| 3 | Silvers, Jason | President & CFO | daughter | Buy | 3022026 | 16.00 | 1,000 | 16,000 | 8,000 | Form |
| 4 | Silvers, Jason | President & CFO | son | Buy | 3022026 | 16.00 | 1,000 | 16,000 | 16,000 | Form |
| 5 | Afeyan, Noubar | Flagship Pioneering Fund VII, L.P. | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 244,235,584 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nally, Michael | Chief Executive Officer | Direct | Buy | 3062026 | 12.00 | 20,000 | 240,000 | 6,872,484 | Form |
| 2 | Grous, Beth | Chief People Officer | Spouse | Buy | 3022026 | 16.00 | 300 | 4,800 | 4,800 | Form |
| 3 | Silvers, Jason | President & CFO | daughter | Buy | 3022026 | 16.00 | 1,000 | 16,000 | 8,000 | Form |
| 4 | Silvers, Jason | President & CFO | son | Buy | 3022026 | 16.00 | 1,000 | 16,000 | 16,000 | Form |
| 5 | Afeyan, Noubar | Flagship Pioneering Fund VII, L.P. | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 244,235,584 | Form | |
| 6 | Afeyan, Noubar | FPN II, L.P. | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 69,444,032 | Form | |
| 7 | Afeyan, Noubar | Pioneering Medicines 02, LLC | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 25,000,000 | Form | |
| 8 | Mendillo, Jane L | Direct | Buy | 3022026 | 16.00 | 1,500 | 24,000 | 24,000 | Form | |
| 9 | Afeyan, Noubar | Flagship Pioneering Fund VII, L.P. | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 244,235,584 | Form | |
| 10 | Afeyan, Noubar | FPN II, L.P. | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 69,444,032 | Form | |
| 11 | Afeyan, Noubar | Pioneering Medicines 02, LLC | Buy | 3022026 | 16.00 | 1,562,500 | 25,000,000 | 25,000,000 | Form |
Generate Biomedicines — Investor Video Playlist
Products & Services
EmTech AI 2026 | From Models to Medicines with Gevorg Grigoryan.
Investor / Analyst
New Street Research, "AI Transforming Pharma" A conversation with Generate:Biomedicines
Leadership
HumanX 2025, "AI in Drug Discovery: Pioneering a New Era of Medicine"
Investor / Analyst
Flagship Pioneering CEO Chat with Mike Nally at the 2025 J.P. Morgan Healthcare Conference
Products & Services
Gevorg Grigoryan Joins VantAI’s Generative AI in Drug Discovery Series
Leadership
Generate:Biomedicine 6-Year Journey
Investor / Analyst
Flagship Pioneering CEO Chat with Mike Nally at the 2024 J.P. Morgan Healthcare Conference
Leadership
Mike Nally at the 2024 Montgomery Summit
Leadership
Mike Nally on Data in Biotech Podcast
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/9/2026